MarketCap
Facebook
X
Telegram
Novan Market Cap | NOVN
As of October 26, 2026 Novan has a market cap of $ 2.64 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Novan
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.2 M | 62.3 M | 140 M | 57.8 M | 320 M | 503 M | 902 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 902 M | 26.2 M | 288 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
CNS Pharmaceuticals
CNSP
|
1.06 M | $ 4.53 | -8.85 % | $ 2.01 M |  USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Curis
CRIS
|
9.48 M | $ 0.37 | -4.25 % | $ 4.87 M | USA |
 |
Moderna
MRNA
|
19.4 B | $ 196.26 | -1.92 % | $ 76.3 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
318 M | $ 10.55 | 0.14 % | $ 833 M | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
307 M | $ 7.58 | 3.48 % | $ 1.09 B | USA |
 |
Neurocrine Biosciences
NBIX
|
11.9 B | $ 144.09 | 0.97 % | $ 14.3 B | USA |
 |
Daré Bioscience
DARE
|
16.9 M | $ 0.65 | 0.81 % | $ 7.27 M | USA |
 |
Minerva Neurosciences
NERV
|
61.8 M | $ 2.22 | -3.42 % | $ 18.8 M | USA |
 |
Nektar Therapeutics
NKTR
|
1.09 B | $ 37.37 | 0.39 % | $ 630 M | USA |
 |
Nkarta
NKTX
|
158 M | $ 1.81 | 0.84 % | $ 134 M | USA |
 |
NanoViricides
NNVC
|
30.3 M | $ 1.36 | -3.55 % | $ 27.5 M | USA |
 |
Editas Medicine
EDIT
|
206 M | $ 2.38 | -0.63 % | $ 211 M | USA |
 |
Nurix Therapeutics
NRIX
|
1.57 B | $ 25.49 | 0.59 % | $ 2.21 B | USA |
 |
Intellia Therapeutics
NTLA
|
776 M | $ 11.18 | -0.27 % | $ 1.21 B | USA |
 |
Novo Nordisk A/S
NVO
|
219 B | $ 38.95 | -0.23 % | $ 173 B |  Danmark |
 |
Novartis AG
NVS
|
316 B | $ 153.68 | 1.67 % | $ 298 B |  Schweiz |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 14.13 | 1.87 % | $ 914 M | USA |
 |
Ocular Therapeutix
OCUL
|
1.71 B | $ 6.51 | 0.15 % | $ 1.22 B | USA |
 |
NuCana plc
NCNA
|
85.4 B | $ 1.03 | 4.54 % | $ 11.6 B |  Britain |
 |
Evogene Ltd.
EVGN
|
6.38 M | $ 0.36 | -1.02 % | $ 2.83 M |  Israel |
 |
BioVie
BIVI
|
2.44 M | $ 1.33 | 7.26 % | $ 1.96 M | USA |
 |
Omeros Corporation
OMER
|
671 M | $ 16.43 | -0.84 % | $ 1.04 B | USA |
 |
Oncolytics Biotech
ONCY
|
32.6 M | $ 0.47 | -5.51 % | $ 45.1 M |  Canada |
 |
ORIC Pharmaceuticals
ORIC
|
1.02 B | $ 9.66 | -26.65 % | $ 848 M | USA |
 |
Ovid Therapeutics
OVID
|
299 M | $ 2.17 | 0.69 % | $ 283 M | USA |
 |
Pliant Therapeutics
PLRX
|
81.6 M | $ 0.84 | -2.22 % | $ 51.5 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
85.6 M | $ 1.18 | -7.09 % | $ 62 M | USA |
 |
Praxis Precision Medicines
PRAX
|
7.31 B | $ 263.47 | 4.15 % | $ 5.93 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
277 M | $ 3.68 | 1.38 % | $ 283 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
162 M | $ 1.24 | -4.26 % | $ 131 M |  Niderland |
 |
Prothena Corporation plc
PRTA
|
251 M | $ 8.43 | 2.8 % | $ 454 M | USA |
 |
Pulmatrix
PULM
|
5.08 B | $ 1.46 | -1.35 % | $ 5.33 B | USA |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 126.85 | 0.97 % | $ 15.2 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
2.01 B | $ 15.91 | 1.66 % | $ 1.57 B | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
12.3 B | $ 13.75 | 4.21 % | $ 11.5 B |  India |
 |
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 36.69 | 1.55 % | $ 2.11 B | USA |
 |
Heron Therapeutics
HRTX
|
198 M | $ 0.3 | -0.26 % | $ 50 M | USA |
 |
Rafael Holdings
RFL
|
39.4 M | $ 1.26 | -1.17 % | $ 37.1 M | USA |
 |
Relay Therapeutics
RLAY
|
546 M | $ 18.25 | 0.36 % | $ 3.13 B | USA |
 |
Regeneron Pharmaceuticals
REGN
|
81.3 B | $ 802.12 | -0.36 % | $ 83.9 B | USA |
 |
Passage Bio
PASG
|
18.8 M | $ 3.36 | -0.33 % | $ 10.8 M | USA |
 |
Royalty Pharma plc
RPRX
|
18.9 B | $ 64.58 | 1.13 % | $ 27.8 B | USA |
 |
Pfizer
PFE
|
155 B | $ 29.78 | -0.8 % | $ 169 B | USA |
 |
Forte Biosciences
FBRX
|
335 M | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunome
IMNM
|
1.89 B | $ 17.87 | -0.67 % | $ 1.56 B | USA |
 |
Immuron Limited
IMRN
|
231 M | $ 0.98 | 3.05 % | $ 226 M |  Australia |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 89.78 | 0.57 % | $ 5.83 B | USA |
 |
Sana Biotechnology
SANA
|
995 M | $ 2.35 | 0.64 % | $ 595 M | USA |
 |
Inhibikase Therapeutics
IKT
|
160 M | $ 1.51 | -5.03 % | $ 148 M | USA |